These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24374114)

  • 21. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prospective evaluation of the early course of schizophrenia in men and women after a first psychiatric hospitalization].
    Jaracz K; Górna K; Kiejda J; Rybakowski J
    Psychiatr Pol; 2008; 42(1):33-46. PubMed ID: 18567402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
    Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
    Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of symptoms for quality of life in first-episode schizophrenia.
    Chugh PK; Rehan HS; Unni KE; Sah RK
    Nord J Psychiatry; 2013 Jun; 67(3):153-8. PubMed ID: 22587635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia].
    Sauvanaud F; Kebir O; Vlasie M; Doste V; Amado I; Krebs MO
    Encephale; 2017 May; 43(3):235-240. PubMed ID: 27658989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
    de Bartolomeis A; Prinzivalli E; Callovini G; D'Ambrosio L; Altavilla B; Avagliano C; Iasevoli F
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():356-366. PubMed ID: 28887181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cannabis and schizophrenia: demographic and clinical correlates].
    Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
    Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterizing trajectories of cognitive functioning in older adults with schizophrenia: does method matter?
    Thompson WK; Savla GN; Vahia IV; Depp CA; O'Hara R; Jeste DV; Palmer BW
    Schizophr Res; 2013 Jan; 143(1):90-6. PubMed ID: 23218560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.